Top Markets
Coin of the day
Faes Farma, S.A. Faes Farma, S.A.

Faes Farma, S.A.

FAE
株式のランク #7179
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research,... Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
株価
$5.43
時価総額
$1.69B
変化(1日)
0.11%
変化(1年)
10.15%
ES
取引 Faes Farma, S.A. (FAE)

カテゴリー

Faes Farma, S.A.(FAE)の利益
2026 時点の利益 TTM: 0
Faes Farma, S.A. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Faes Farma, S.A. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。